[go: up one dir, main page]

DE69703294D1 - Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten - Google Patents

Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten

Info

Publication number
DE69703294D1
DE69703294D1 DE69703294T DE69703294T DE69703294D1 DE 69703294 D1 DE69703294 D1 DE 69703294D1 DE 69703294 T DE69703294 T DE 69703294T DE 69703294 T DE69703294 T DE 69703294T DE 69703294 D1 DE69703294 D1 DE 69703294D1
Authority
DE
Germany
Prior art keywords
taxotere
compositions
docosahexaenoic acid
conjugate containing
containing cis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69703294T
Other languages
English (en)
Other versions
DE69703294T2 (de
Inventor
O Bradley
E Shashoua
L Webb
S Swindell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Regent Inc
Original Assignee
Protarga Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protarga Inc filed Critical Protarga Inc
Publication of DE69703294D1 publication Critical patent/DE69703294D1/de
Application granted granted Critical
Publication of DE69703294T2 publication Critical patent/DE69703294T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69703294T 1996-05-22 1997-05-22 Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten Expired - Lifetime DE69703294T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65142996A 1996-05-22 1996-05-22
PCT/US1997/008866 WO1997044026A1 (en) 1996-05-22 1997-05-22 Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere

Publications (2)

Publication Number Publication Date
DE69703294D1 true DE69703294D1 (de) 2000-11-16
DE69703294T2 DE69703294T2 (de) 2001-05-17

Family

ID=24612833

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69703294T Expired - Lifetime DE69703294T2 (de) 1996-05-22 1997-05-22 Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten

Country Status (9)

Country Link
US (1) US6080877A (de)
EP (1) EP0914116B1 (de)
JP (1) JP4172726B2 (de)
AT (1) ATE196844T1 (de)
CA (1) CA2255615C (de)
DE (1) DE69703294T2 (de)
DK (1) DK0914116T3 (de)
ES (1) ES2151277T3 (de)
WO (1) WO1997044026A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EP0870510A3 (de) * 1997-04-11 1999-09-15 Eli Lilly And Company Synergistische Zusammensetzung enthaltend Cryptophycinderivate und synergistische mikrotubuli Mitteln
US7288665B1 (en) * 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9804361D0 (en) * 1998-03-02 1998-04-22 Scotia Holdings Plc Cancer treatment
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
DE69919695T2 (de) * 1998-06-05 2005-09-15 Board of Regents, The University of Texas System, Austin Texaphyrin-konjugate und ihre anwendiung
GB9904386D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
HK1040486A1 (zh) * 1999-03-09 2002-06-14 Luitpold Pharmaceuticals, Inc. 脂肪酸-抗癌共軛和其用途
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
WO2001077137A1 (en) * 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
CZ302498B6 (cs) * 1999-11-15 2011-06-15 Pharma Mar, S. A. Farmaceutický prípravek obsahující aplidin pro lécení rakovinových onemocnení
HK1049997B (en) 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
JP2003522172A (ja) * 2000-02-02 2003-07-22 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド 抗腫瘍剤としてのc10エステル置換タキサン
AR030188A1 (es) * 2000-02-02 2003-08-13 Univ Florida State Res Found Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos
US6649632B2 (en) 2000-02-02 2003-11-18 Fsu Research Foundation, Inc. C10 ester substituted taxanes
GB0003201D0 (en) * 2000-02-11 2000-04-05 Pharmacia & Upjohn Spa Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
AU7007001A (en) 2000-06-22 2002-01-02 Nitromed Inc Nitrosated and nitrosylated taxanes, compositions and methods of use
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
US6624317B1 (en) 2000-09-25 2003-09-23 The University Of North Carolina At Chapel Hill Taxoid conjugates as antimitotic and antitumor agents
CZ2003993A3 (cs) * 2000-10-12 2004-02-18 Pharma Mar, S. A. Léčivo pro léčení rakoviny podáváním aplidinu nebo analogu aplidinu a protektoru kosterního svalstva
WO2002076404A2 (en) * 2001-03-23 2002-10-03 Protarga, Inc. Fatty alcohol drug conjugates
AU2002303164A1 (en) * 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
IL157993A0 (en) 2001-03-23 2004-03-28 Napro Biotherapeutics Inc Molecular conjugates for use in cancer treatment and methods for the preparation thereof
EP1401477A4 (de) * 2001-05-25 2005-02-02 Human Genome Sciences Chemokin-beta-1-fusionsproteine
CA2354471A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C10 ester substituted taxanes
CA2354486A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C7 ester substituted taxanes
SG129990A1 (en) * 2001-08-01 2007-03-20 Univ Florida State Res Found C10 ester substituted taxanes
SG125889A1 (en) * 2001-08-01 2006-10-30 Univ Florida State Res Found C7 ester subsituted taxanes
US20050004012A1 (en) * 2001-10-19 2005-01-06 Ramon Mangues Use of aplidine for the treatment of pancreatic cancer
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
EP2277889B1 (de) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusionsproteine von Albumin und Interferon beta
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
BR0313197A (pt) 2002-08-02 2005-08-09 Immunogen Inc Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
ATE406171T1 (de) * 2003-03-12 2008-09-15 Dana Farber Cancer Inst Inc Aplidine zur behandlung von multiplem myelom
JP4669393B2 (ja) * 2003-05-26 2011-04-13 浩 前田 抗腫瘍剤及びその製造方法
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
CA2543722C (en) 2003-10-29 2011-01-04 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
RU2340616C2 (ru) * 2003-10-29 2008-12-10 Сонус Фармасьютикалз, Инк. Токоферол-модифицированные терапевтические лекарственные соединения
US7820839B2 (en) * 2003-10-30 2010-10-26 The Research Foundation Of State University Of New York Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
PE20050693A1 (es) 2004-02-13 2005-09-27 Univ Florida State Res Found Taxanos sustituidos con esteres de ciclopentilo en c10
WO2005087222A1 (en) 2004-03-05 2005-09-22 Florida State University Research Foundation, Inc. C7 lactyloxy-substituted taxanes
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
CA2561513C (en) 2004-03-29 2019-02-26 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20060216767A1 (en) * 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
WO2008021242A2 (en) * 2006-08-10 2008-02-21 The Research Foundation Of State University Of New York Fluorotaxoid-fatty acid conjugates and pharmaceutical compositions thereof
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
UA99836C2 (en) * 2007-09-26 2012-10-10 Маунт Синай Скул Оф Медсин Azacytidine analogue and using thereof
JP2011517455A (ja) 2008-03-31 2011-06-09 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド C(10)エチルエステルおよびc(10)シクロプロピルエステル置換タキサン
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
CN109310771A (zh) * 2016-06-03 2019-02-05 埃维克辛公司 包含多不饱和酮与皮质甾类化合物的联合疗法
GB201609735D0 (en) * 2016-06-03 2016-07-20 Avexxin As Combination therapy
SI3490560T1 (sl) 2016-07-29 2025-04-30 Janssen Pharmaceutica, N.V. Niraparib za uporabo pri metodi zdravljenja raka prostate
US11351127B2 (en) 2016-09-21 2022-06-07 Avexxin As Pharmaceutical composition

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351831A (en) * 1977-11-02 1982-09-28 Massachusetts Institute Of Technology Process and composition for treating disorders by administering isoxsurpine and choline
IT7927748A0 (it) * 1979-11-30 1979-11-30 Simes Derivati dell'acido 6,6'-diapopsi psicarotenedioico e relativi procedimenti di preparazione.
US4346085A (en) * 1980-02-29 1982-08-24 Massachusetts Institute Of Technology Process and composition for treating disorders by administering amphetamine and choline
US4636494A (en) * 1981-01-30 1987-01-13 Massachusetts Institute Of Technology Process and composition for treating disorders by administering amphetamine and choline
JPS58177953A (ja) * 1982-04-13 1983-10-18 Eisai Co Ltd ポリプレニルカルボン酸アミドおよびその製造方法
JPS5925327A (ja) * 1982-07-31 1984-02-09 Hidematsu Hirai 抗腫瘍性複合体の製造方法
EP0133795B1 (de) * 1983-08-01 1989-01-18 THE McLEAN HOSPITAL CORPORATION Gaba-Ester und gaba-analoge Ester
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
US4684646A (en) * 1984-06-26 1987-08-04 Merck & Co., Inc. 2-acylaminomethyl-1,4-benzodiazepine derivatives as CCK-antagonists
US4554272A (en) * 1985-01-25 1985-11-19 Merck & Co., Inc. Substituted quinazolino-1,4-benzodiazepin-6,9-diones and their preparation
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5246726A (en) * 1986-03-21 1993-09-21 Efamol Ltd. Iron-containing composition and method for treatment of cancer
FR2601676B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
GB8716305D0 (en) * 1987-07-10 1987-08-19 Raychem Ltd Electrical wire
JPH01153629A (ja) * 1987-12-11 1989-06-15 Nippon Oil & Fats Co Ltd 制癌剤
JPH01203331A (ja) * 1988-02-05 1989-08-16 Rikagaku Kenkyusho 制癌剤
US4933324A (en) * 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
US4939174A (en) * 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
JPH01287022A (ja) * 1988-05-12 1989-11-17 Nippon Oil & Fats Co Ltd 抗癌剤耐性克服剤
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
CH676909A5 (de) * 1988-12-23 1991-03-28 Nestle Sa
HU207287B (en) * 1989-01-17 1993-03-29 Biosignal Kutato Fejlesztoe Kf Polyene fatty acid derivatives of tyrozine-quinaze inhibiting activity and pharmaceutical composition containing them as active component
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
GB8918294D0 (en) * 1989-08-10 1989-09-20 Efamol Holdings Pharmaceutical compositions
GB9001121D0 (en) * 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
IT1254517B (it) * 1992-03-06 1995-09-25 Indena Spa 14-beta idrossi-10-deacetil-baccatina iii, suoi derivati, loro prepazione ed impiego terapeutico
IT1254515B (it) * 1992-03-06 1995-09-25 Indena Spa Tassani di interesse oncologico, loro metodo di preparazione ed uso
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
JPH0616548A (ja) * 1992-06-30 1994-01-25 Sagami Chem Res Center 組織異常増殖抑制剤
US5453521A (en) * 1992-10-05 1995-09-26 Rhone-Poulenc Rorer S.A. Process for obtaining 10-deacetylbaccatin III
FR2696461B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
US5356928A (en) * 1992-11-06 1994-10-18 Hauser Chemical Research, Inc. Cytotoxic agents
FR2697841B1 (fr) * 1992-11-12 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
CA2150470A1 (en) * 1992-11-30 1994-06-09 S.P.I. Synthetic Peptides Incorporated Polyunsaturated fatty acyl-peptide composition
FR2698871B1 (fr) * 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5336684A (en) * 1993-04-26 1994-08-09 Hauser Chemical Research, Inc. Oxidation products of cephalomannine
FR2707293A1 (fr) * 1993-07-08 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2712288B1 (fr) * 1993-11-08 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2712289B1 (fr) * 1993-11-08 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
FR2721023B1 (fr) * 1994-06-09 1996-07-12 Rhone Poulenc Rorer Sa Nouveaux Taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2721928A1 (fr) * 1994-07-04 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH0827010A (ja) * 1994-07-19 1996-01-30 Nichinichi Seiyaku Kk 制癌免疫療法剤
JPH08163991A (ja) * 1994-12-15 1996-06-25 Mitsui Petrochem Ind Ltd タキサン型ジテルペンの製造方法
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
GB9508823D0 (en) * 1995-05-01 1995-06-21 Scotia Holdings Plc Drug Derivatives
JPH0925231A (ja) * 1995-07-13 1997-01-28 Sagami Chem Res Center 癌転移抑制剤
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes

Also Published As

Publication number Publication date
EP0914116A1 (de) 1999-05-12
JP4172726B2 (ja) 2008-10-29
JP2000511188A (ja) 2000-08-29
CA2255615A1 (en) 1997-11-27
AU3142497A (en) 1997-12-09
US6080877A (en) 2000-06-27
WO1997044026A1 (en) 1997-11-27
DK0914116T3 (da) 2000-11-20
EP0914116B1 (de) 2000-10-11
AU722912B2 (en) 2000-08-17
DE69703294T2 (de) 2001-05-17
ES2151277T3 (es) 2000-12-16
CA2255615C (en) 2006-08-29
ATE196844T1 (de) 2000-10-15

Similar Documents

Publication Publication Date Title
DE69703294D1 (de) Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
DE69708100D1 (de) Konjugate von cis-docosahexaensäure und paclitaxel
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DK1019060T3 (da) Androgensynteseinhibitorer
ATE314844T1 (de) Verfahren und zusammensetzungen zur verabreichung von taxanen
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
PT839154E (pt) Peptidos e composicoes biologicamente activos sua utilizacao
DE69830336D1 (de) Ein kovalentes konjugat von clozapine und einer fettsäure und dessen verwendung zur behandlung von schizophrenie
ATE273025T1 (de) Dha-pharmazeutisches produkt konjugate
MX9708401A (es) Genes reguladores de la cromatina.
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
BR9912327A (pt) Inibidores da uroquinase
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
BG103832A (en) Leptin as tumour cells proliferation inhibitor
DE69918413D1 (de) Auswahlverfahren von hla-g exprimierenden tumoren, die durch antikrebsmittel behandelbar sind, und deren verwendungen
YU13301A (sh) Muskarinski agonisti i antagonisti
TR200101756T2 (tr) Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller.
ATE381327T1 (de) Cethylmyristat und cetylpalmitat zurbehandlung von ekzemen und/oder psoriasis
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
BR9915955A (pt) Composição cosmética para cuidado com a pele, processo cosmético para tratar uma pele envelhecida e uso de 4- cromanona

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LUITPOLD PHARMACEUTICALS, INC., SHIRLEY, N.Y., US